CR-002 for Cancer
(APOLLO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
Are You a Good Fit for This Trial?
This trial is for adults with advanced or spreading solid tumors, such as cancers of the lung, ovary, endometrium, gallbladder, esophagus, biliary tract, cervix, or head and neck. Participants must have cancer that has come back or not responded to other treatments.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- CR-002
Trial Overview
The study is testing a new drug called CR-002 given alone (monotherapy) to find out what dose is safest and best tolerated in people with various advanced cancers.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Escalating dose levels of CR-002 will be tested to define the maximum tolerated dose of CR-002 in participants with locally advanced or metastatic solid tumors who are refractory to or unable to tolerate standard of care treatment, or for whom standard of care treatment is unavailable.
Escalating dose levels of CR-002 will be tested in indication-specific cohort populations.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Crescent Biopharma, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.